medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2021-20-160-166medsovet-6595Research ArticleКЛИНИЧЕСКИЕ РАЗБОРЫCLINICAL ANALYZESКлинический случай лечения метастатического люминального рака молочной железыClinical case of the treatment of metastatic luminal breast cancerhttps://orcid.org/0000-0001-8340-7962НасретдиновА. Ф.NasretdinovA. F.

врач-онколог амбулаторного отделения противоопухолевой лекарственной терапии, 

450054, Республика Башкоторстан, Уфа, проспект Октября, д. 73/1

Oncologist at the Outpatient Department of Anticancer Drug Therapy, 

73/1, Oktyabrya Ave., Ufa, Republic of Bashkortostan, 450054

rkodrb@yandex.ruhttps://orcid.org/0000-0003-0996-5995СултанбаевА. В.SultanbaevA. V.

к.м.н., заведующий отделом противоопухолевой лекарственной терапии, 

450054, Республика Башкоторстан, Уфа, проспект Октября, д. 73/1

Cand. Sci. (Med.), Head of the Department of Anticancer Drug Therapy, 

73/1, Oktyabrya Ave., Ufa, Republic of Bashkortostan, 450054

rkodrb@yandex.ruhttps://orcid.org/0000-0003-3734-2779МеньшиковК. В.MenshikovK. V.

к.м.н., доцент кафедры онкологии с курсами онкологии и патологической анатомии Института дополнительного профессионального образования, 450000, Республика Башкоторстан, Уфа, ул. Ленина, д. 3;

врач-онколог отдела химиотерапии, 450054, Республика Башкоторстан, Уфа, проспект Октября, д. 73/1

Cand. Sci. (Med.), Associate Professor of the Department of Oncology with Oncology and Pathology Courses, Institute of Continuing Professional Education, 3, Lenin St., Ufa, Republic of Bashkortostan, 450000;

Oncologist at the Chemotherapy Department, 73/1, Oktyabrya Ave., Ufa, Republic of Bashkortostan, 450054

kmenshikov80@bk.ruhttps://orcid.org/0000-0003-1185-977XМусинШ. И.MusinSh. I.

к.м.н., заведующий хирургическим отделением № VI, 450054, Республика Башкоторстан, Уфа, проспект Октября, д. 73/1;

доцент кафедры онкологии с курсами онкологии и патологической анатомии Института дополнительного профессионального образования, 450000, Республика Башкоторстан, Уфа, ул. Ленина, д. 3

Cand. Sci. (Med.), Head of the Surgery Department No. 6, 73/1, Oktyabrya Ave., Ufa, Republic of Bashkortostan, 450054;

Associate Professor of the Department of Oncology with Courses Oncology and Pathological Anatomy,Institute of Additional Professional Education, 3, Lenin St., Ufa, Republic of Bashkortostan, 450000

rkodrb@yandex.ruhttps://orcid.org/0000-0001-5926-0446СултанбаеваН. И.SultanbaevaN. I.

Надежда Ивановна, врач-онколог отделения противоопухолевой лекарственной терапии № 1, 

450054, Республика Башкоторстан, Уфа, проспект Октября, д. 73/1

Oncologist at the Department of Anticancer Drug Therapy No. 1, 

73/1, Oktyabrya Ave., Ufa, Republic of Bashkortostan, 450054

nd.sultan@rambler.ruhttps://orcid.org/0000-0002-8461-9243ИзмайловА. А.IzmailovA. A.

д.м.н., профессор кафедры урологии Института дополнительного профессионального образования, 450000, Республика Башкоторстан, Уфа, ул. Ленина, д. 3;

главный врач, 450054, Республика Башкоторстан, Уфа, проспект Октября, д. 73/1

Dr. Sci. (Med.), Professor of the Department of Urology, Institute of Continuing Professional Education, 73/1, Oktyabrya Ave., Ufa, Republic of Bashkortostan, 450054;

Chief Medical Officer, 73/1, Oktyabrya Ave., Ufa, Republic of Bashkortostan, 450054

 

ufa.rkod@doctorrb.ruhttps://orcid.org/0000-0002-6769-7194АюповР. Т.AyupovR. T.

к.м.н., заместитель главного врача по медицинской части, 

450054, Республика Башкоторстан, Уфа, проспект Октября, д. 73/1

Cand. Sci. (Med.), Deputy Chief Physician for Medical Affairs, 

73/1, Oktyabrya Ave., Ufa, Republic of Bashkortostan, 450054

ru2003@bk.ruРеспубликанский клинический онкологический диспансерРоссияRepublican Clinical Oncology DispensaryRussian FederationБашкирский государственный медицинский университет; Республиканский клинический онкологический диспансерРоссияBashkir State Medical University; Republican Clinical Oncology DispensaryRussian FederationРеспубликанский клинический онкологический диспансер; Башкирский государственный медицинский университетРоссияRepublican Clinical Oncology Dispensary; Bashkir State Medical UniversityRussian Federation202112122021020160166Copyright © Насретдинов А.Ф., Султанбаев А.В., Меньшиков К.В., Мусин Ш.И., Султанбаева Н.И., Измайлов А.А., Аюпов Р.Т., 20212021Насретдинов А.Ф., Султанбаев А.В., Меньшиков К.В., Мусин Ш.И., Султанбаева Н.И., Измайлов А.А., Аюпов Р.Т.Nasretdinov A.F., Sultanbaev A.V., Menshikov K.V., Musin S.I., Sultanbaeva N.I., Izmailov A.A., Ayupov R.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/6595

Современные возможности гормонотерапии открывают для пациента перспективу длительного, комфортного и сравнительно малотоксичного лечения. Долгое время наличие висцеральных метастазов побуждало онкологов отказываться от гормонотерапии в  пользу цитостатических средств. В  настоящее время даже при наличии висцеральных метастазов клиническими рекомендациями допускается гормональная терапия в условиях отсутствия висцерального криза. В частности, препаратами, позволившими значительно улучшить результаты гормонотерапии, стали так называемые CDK 4/6 ингибиторы, представленные на российском рынке палбоциклибом, рибоциклибом и абемациклибом. Каждый из них продемонстрировал свою эффективность в  клинических исследованиях. Более того, часты случаи, демонстрирующие преимущества указанной терапии в реальной клинической практике. В статье представлен клинический случай лечения распространенного гормонопозитивного рака молочной железы. Продемонстрирована эффективность лечения CDK 4/6 ингибиторами, проведен сравнительный анализ с данными, полученными в ходе клинических исследований, а также разбор тактики лечения цитомегаловирусной инфекции роговицы на фоне терапии рибоциклибом. 

Hormone therapy currently open up the prospect of long-term, comfortable and relatively low-toxic treatment for patients with hormone receptor – positive advanced breast cancer. For a long time, the presence of visceral metastases prompted oncologists to abandon hormone therapy in favor of cytostatic agents. Now days, even in the presence of visceral metastases, clinical guidelines allow use of modern hormonal therapy in the absence of a visceral crisis. In particular, the so-called CDK 4/6 inhibitors, presented on the Russian market by drugs: palbociclib, ribociclib and abemacyclib, became the drugs that significantly improved the  results of  hormone therapy. Each of  them has demonstrated its effectiveness in  clinical trials; moreover, there are lots of clinical cases demonstrating the benefits of this therapy in real clinical practice. The article presents a clinical case of treatment of advanced hormone receptor-positive breast cancer. The effectiveness of treatment with CDK 4/6 inhibitors has been demonstrated, a comparatively analysed with the data obtained in the course of clinical trials. The analysis of the tactics of treatment of cytomegalovirus infection of the cornea during therapy with ribociclib was carried out. 

клинический случайлюминальный рак молочной железыCDK 4/6 ингибиторырибоциклибцитомегаловирусный кератитclinical caseluminal breast cancerCDK 4/6 inhibitorsribociclibcytomegalovirus keratitisReferencesKlijn J.G., Blamey R.W., Boccardo F., Tominaga T., Duchateau L., Sylvester R. Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials. J Clin Oncol. 2001;19(2):343–353. https://doi.org/10.1200/JCO.2001.19.2.343.Klijn J.G., Blamey R.W., Boccardo F., Tominaga T., Duchateau L., Sylvester R. Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials. J Clin Oncol. 2001;19(2):343–353. https://doi.org/10.1200/JCO.2001.19.2.343.Jordan V.C. Tamoxifen Treatment for Breast Cancer: Concept to Gold Standard. Oncology (Williston Park). 1997;11(2–S1):7–13. Available at: https://pubmed.ncbi.nlm.nih.gov/9065921/.Jordan V.C. Tamoxifen Treatment for Breast Cancer: Concept to Gold Standard. Oncology (Williston Park). 1997;11(2–S1):7–13. Available at: https://pubmed.ncbi.nlm.nih.gov/9065921/.Clemett D., Lamb H.M. Exemestane: A Review of Its Use in Postmenopausal Women with Advanced Breast Cancer. Drugs. 2000;59(6):1279–1296. https://doi.org/10.2165/00003495-200059060-00007.Clemett D., Lamb H.M. Exemestane: A Review of Its Use in Postmenopausal Women with Advanced Breast Cancer. Drugs. 2000;59(6):1279–1296. https://doi.org/10.2165/00003495-200059060-00007.Baselga J., Campone M., Piccart M., Burris H.A. 3rd, Rugo H.S., Sahmoud T. et al. Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2012;366(6):520–529. https://doi.org/10.1056/NEJMoa1109653.Baselga J., Campone M., Piccart M., Burris H.A. 3rd, Rugo H.S., Sahmoud T. et al. Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2012;366(6):520–529. https://doi.org/10.1056/NEJMoa1109653.Robertson J.F.R., Bondarenko I.M., Trishkina E., Dvorkin M., Panasci L., Manikhas A. et al. Fulvestrant 500 mg versus Anastrozole 1 mg for Hormone Receptor-Positive Advanced Breast Cancer (FALCON): An International, Randomised, Double-Blind, Phase 3 Trial. Lancet. 2016;388(10063):2997– 3005. https://doi.org/10.1016/S0140-6736(16)32389-3.Robertson J.F.R., Bondarenko I.M., Trishkina E., Dvorkin M., Panasci L., Manikhas A. et al. Fulvestrant 500 mg versus Anastrozole 1 mg for Hormone Receptor-Positive Advanced Breast Cancer (FALCON): An International, Randomised, Double-Blind, Phase 3 Trial. Lancet. 2016;388(10063):2997– 3005. https://doi.org/10.1016/S0140-6736(16)32389-3.Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S. et al. Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant versus Anastrozole in Postmenopausal Women with Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial. J Clin Oncol. 2002;20(16):3386–3395. https://doi.org/10.1200/JCO.2002.10.058.Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S. et al. Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant versus Anastrozole in Postmenopausal Women with Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial. J Clin Oncol. 2002;20(16):3386–3395. https://doi.org/10.1200/JCO.2002.10.058.Chia S., Gradishar W., Mauriac L., Bines J., Amant F., Federico M. et al. Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared with Exemestane after Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone Receptor-Positive, Advanced Breast Cancer: Results from EFECT. J Clin Oncol. 2008;26(10):1664–1670. https://doi.org/10.1200/JCO.2007.13.5822.Chia S., Gradishar W., Mauriac L., Bines J., Amant F., Federico M. et al. Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared with Exemestane after Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone Receptor-Positive, Advanced Breast Cancer: Results from EFECT. J Clin Oncol. 2008;26(10):1664–1670. https://doi.org/10.1200/JCO.2007.13.5822.Spring L.M., Wander S.A., Zangardi M., Bardia A. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Curr Oncol Rep. 2019;21(3):25. https://doi.org/10.1007/s11912-019-0769-3.Spring L.M., Wander S.A., Zangardi M., Bardia A. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Curr Oncol Rep. 2019;21(3):25. https://doi.org/10.1007/s11912-019-0769-3.Cristofanilli M., Turner N.C., Bondarenko I., Ro J., Im S.A., Masuda N. et al. Fulvestrant plus Palbociclib versus Fulvestrant plus Placebo for Treatment of Hormone-Receptor-Positive, HER2-Negative Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial. Lancet Oncol. 2016;17(4):425–439. https://doi.org/10.1016/S1470- 2045(15)00613-0.Cristofanilli M., Turner N.C., Bondarenko I., Ro J., Im S.A., Masuda N. et al. Fulvestrant plus Palbociclib versus Fulvestrant plus Placebo for Treatment of Hormone-Receptor-Positive, HER2-Negative Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial. Lancet Oncol. 2016;17(4):425–439. https://doi.org/10.1016/S1470- 2045(15)00613-0.Finn R.S., Martin M., Rugo H.S., Jones S., Im S.A., Gelmon K. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925–1936. https://doi.org/10.1056/NEJMoa1607303.Finn R.S., Martin M., Rugo H.S., Jones S., Im S.A., Gelmon K. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925–1936. https://doi.org/10.1056/NEJMoa1607303.Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G.S., Paluch-Shimon S. et al Updated Results from MONALEESA-2, A Phase III Trial of First-Line Ribociclib plus Letrozole versus Placebo plus Letrozole in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Ann Oncol. 2018;29(7):1541–1547. https://doi.org/10.1093/annonc/mdy155.Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G.S., Paluch-Shimon S. et al Updated Results from MONALEESA-2, A Phase III Trial of First-Line Ribociclib plus Letrozole versus Placebo plus Letrozole in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Ann Oncol. 2018;29(7):1541–1547. https://doi.org/10.1093/annonc/mdy155.Slamon D.J., Neven P., Chia S., Fasching P.A., De Laurentiis M., Im S.A. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472. https://doi.org/10.1200/JCO.2018.78.9909.Slamon D.J., Neven P., Chia S., Fasching P.A., De Laurentiis M., Im S.A. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472. https://doi.org/10.1200/JCO.2018.78.9909.Zheng R., Han S., Duan C., Chen K., You Z., Jia J. et al. Role of Taxane and Anthracycline Combination Regimens in the Management of Advanced Breast Cancer: A Meta-Analysis of Randomized Trials. Medicine (Baltimore). 2015;94(17):e803. https://doi.org/10.1097/MD.0000000000000803.Zheng R., Han S., Duan C., Chen K., You Z., Jia J. et al. Role of Taxane and Anthracycline Combination Regimens in the Management of Advanced Breast Cancer: A Meta-Analysis of Randomized Trials. Medicine (Baltimore). 2015;94(17):e803. https://doi.org/10.1097/MD.0000000000000803.Mauri D., Kamposioras K., Tsali L., Bristianou M., Valachis A., Karathanasi I. et al. Overall Survival Benefit for Weekly vs. Three-Weekly Taxanes Regimens in Advanced Breast Cancer: A Meta-Analysis. Cancer Treat Rev. 2010;36(1):69–74. https://doi.org/10.1016/j.ctrv.2009.10.006.Mauri D., Kamposioras K., Tsali L., Bristianou M., Valachis A., Karathanasi I. et al. Overall Survival Benefit for Weekly vs. Three-Weekly Taxanes Regimens in Advanced Breast Cancer: A Meta-Analysis. Cancer Treat Rev. 2010;36(1):69–74. https://doi.org/10.1016/j.ctrv.2009.10.006.Sbitti Y., Slimani K., Debbagh A., Mokhlis A., Kadiri H., Laraqui A. et al. Visceral Crisis Means Short Survival Among Patients With Luminal A Metastatic Breast Cancer: A Retrospective Cohort Study. World J Oncol. 2017;8(4):105–109. https://doi.org/10.14740/wjon1043w.Sbitti Y., Slimani K., Debbagh A., Mokhlis A., Kadiri H., Laraqui A. et al. Visceral Crisis Means Short Survival Among Patients With Luminal A Metastatic Breast Cancer: A Retrospective Cohort Study. World J Oncol. 2017;8(4):105–109. https://doi.org/10.14740/wjon1043w.O J.H., Lodge M.A., Wahl R.L. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology. 2016;280(2):576–584. https://doi.org/10.1148/radiol.2016142043.O J.H., Lodge M.A., Wahl R.L. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology. 2016;280(2):576–584. https://doi.org/10.1148/radiol.2016142043.Tripathy D., Im S.A., Colleoni M., Franke F., Bardia A., Harbeck N. et al. Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-Receptor-Positive, Advanced Breast Cancer (MONALEESA-7): A Randomised Phase 3 Trial. Lancet Oncol. 2018;19(7):904–915. https://doi.org/10.1016/S1470-2045(18)30292-4.Tripathy D., Im S.A., Colleoni M., Franke F., Bardia A., Harbeck N. et al. Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-Receptor-Positive, Advanced Breast Cancer (MONALEESA-7): A Randomised Phase 3 Trial. Lancet Oncol. 2018;19(7):904–915. https://doi.org/10.1016/S1470-2045(18)30292-4.Carmichael A. Cytomegalovirus and the Eye. Eye (Lond). 2012;26(2):237–240. https://doi.org/10.1038/eye.2011.327.Carmichael A. Cytomegalovirus and the Eye. Eye (Lond). 2012;26(2):237–240. https://doi.org/10.1038/eye.2011.327.Spring L.M., Zangardi M.L., Moy B., Bardia A. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist. 2017;22(9):1039–1048. https://doi.org/10.1634/theoncologist.2017-0142.Spring L.M., Zangardi M.L., Moy B., Bardia A. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist. 2017;22(9):1039–1048. https://doi.org/10.1634/theoncologist.2017-0142.Samant T.S., Huth F., Umehara K., Schiller H., Dhuria S.V., Elmeliegy M. et al. Ribociclib Drug-Drug Interactions: Clinical Evaluations and PhysiologicallyBased Pharmacokinetic Modeling to Guide Drug Labeling. Clin Pharmacol Ther. 2020;108(3):575–585. https://doi.org/10.1002/cpt.1950.Samant T.S., Huth F., Umehara K., Schiller H., Dhuria S.V., Elmeliegy M. et al. Ribociclib Drug-Drug Interactions: Clinical Evaluations and PhysiologicallyBased Pharmacokinetic Modeling to Guide Drug Labeling. Clin Pharmacol Ther. 2020;108(3):575–585. https://doi.org/10.1002/cpt.1950.Harrell A.W., Wheeler S.M., Pennick M., Clarke S.E., Chenery R.J. Evidence that Famciclovir (BRL 42810) and Its Associated Metabolites Do Not Inhibit the 6 Beta-Hydroxylation of Testosterone in Human Liver Microsomes. Drug Metab Dispos. 1993;21(1):18–23. Available at: https://pubmed.ncbi.nlm.nih.gov/8095215/.Harrell A.W., Wheeler S.M., Pennick M., Clarke S.E., Chenery R.J. Evidence that Famciclovir (BRL 42810) and Its Associated Metabolites Do Not Inhibit the 6 Beta-Hydroxylation of Testosterone in Human Liver Microsomes. Drug Metab Dispos. 1993;21(1):18–23. Available at: https://pubmed.ncbi.nlm.nih.gov/8095215/.

The authors declare that there are no conflicts of interest present.